Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Debiopharm Signs Agreement With MSM Protein
Debiopharm and MSM Protein (MSM) have sealed an agreement for the development and commercialisation of Debio 0929, to be developed into a new oncology therapeutic drug. Debio 0929
Debiopharm and MSM Protein (MSM) have sealed an agreement for the development and commercialisation of Debio 0929, to be developed into a new oncology therapeutic drug. Debio 0929
Mylan has reported adjusted diluted EPS as $0.32 and $0.65 for the three and six months ended June 30, 2009, compared to $0.20 and $0.29, respectively for the
The Dow Chemical Company has reported a decrease in sales by 31% to $11.3 billion for the second quarter of 2009 from reported sales in the same period
Vertex and Mitsubishi Tanabe Pharma have amended their agreement for the development and commercialization of telaprevir (for the treatment of hepatitis C virus (HCV) infection) in Japan and
Anadys has announced finalization of the protocol for its phase II trial of ANA598, in combination with pegylated interferon-alpha and ribavirin, in hepatitis C patients. Allowance of the
AVI BioPharma has announced the impending strategic move to shift corporate headquarters and much of its leadership team to the greater Seattle area. The company plans to build
Lundbeck has announced the joint decision with its partner, Solvay to stop all joint R&D activities for Solvay’s compound – bifeprunox in development phase. The compound is intended
BioMS Medical and Eli Lilly have reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS).
Cardium has reported plans to develop a DNA-based orthobiologics product portfolio, based on research and development by Cardium’s Tissue Repair Company. It will initially focus on non-union bone
Cornerstone has closed the strategic transaction with Chiesi. As a result of this transaction, the company has received an exclusive 10-year license for the US commercial rights to